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1071-113 Effect of Carvedilol on Major Cardiovascular Events in 
Post-Infarction Patients Treated With Angiotensin 
Converting Enzyme Inhibitors: Further Analysis of the 
Capricorn Trial 
Jonathan Sackner-Bernstein, Ian Ford, Michele Robertson, Mary Ann Lukas, Milton 
Packer, Henry Dargie. St. Luke’sRoosevelt Hospital Center, New York, NY 
Background: The CAPRICORN trial evaluated the effect of carvedilol (CRV) on the risk 
of death and the combined risk of death or cardiovascular hospitakzation (CVH) in post- 
myocardial infarction (Ml) patients with left ventricular dysfunction receiving an ACE 
Inhibitor. CRV reduced the risk of death bv 23% (PzO.03) but reduced the risk of death or ~ 
CVH by only 9% (P=O.30). 
Methods: To explore the reasons for these findings, we analyzed the results of the CAP- 
RICORN trial using endpoints that had been used to show the efficacy of beta-blockers in 
other trials (post-MI beta-blocker trials and the COPERNICUS trial). In the COPERNI- 
CUS trial, the protocol-specified analysrs of CVH focused on major CVH (those for heart 
failure, MI or unstable angina, stroke or TIA, supraventricular or ventricular arrhythmia, 
bradycardia or heart block), whereas the prespecified definition in the CAPRICORN trial 
included all CVH (major or minor) except for procedures. 
Results: CRV reduced the risk of a major event when endpoints were analyzed that had 
been shown in earlier studies to be favorably influenced by beta-blockade. This included 
a 17% reduction in the risk of death or major CVH (defined as in the COPERNICUS 
trial)(P=O.OP). and significant reductions in the risk of fatal or non-fatal MI. 
Conclusions: These findings provide additional support for the efficacy of CRV in post- 
Ml patients already treated with an ACE inhibitor. 
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1071-114 Primary Angioplasty Reduces Mortality in Elderly 
Patients With Right Ventricular Infarction 
Georae S. Hanzel. William W. O’Neill. Mark C. Pica, James A. Goldstein, William 
Beaumont Hospital, Royal Oak, Ml 
Background: In patients with acute right ventricular infarction (RVI), successful reperfu- 
sion by primary angioplasty improves hemodynamics and survival. Yet, it has been 
recently reported that RVI in elderly patients (2 70 years) is associated with in-hospital 
mortality -50%; however, such reports did not address reperfusion status. This study 
was designed to determine whether successful repetfusion exerts beneficial effects on 
mortality in elderly patients with RVI. Methodology: We studied 64 patients t 70 years 
old wth acute Inferior MI undergorng primary angioplasty. The presence of RVI was 
determined by 2D echo performed in the emergency department. In patients with and 
without RVI, we analyzed survival to hospital discharge according to reperfusion status 
(success defined as restoration of TIMI 3 flow). Results: In those with IMI but without RVI, 
reperfusion was successful in 35 (92%)pts, with survival to discharge in 94% of cases. 
RVI was detected in 26 (41%) pts, in whom reperfusron was successful in 21(81%) 
cases, resulting in survival to hospital discharge in 90% of pts which was similar to that 
achieved by reperfusion in IMI without RVI (90% vs. 94%, p = NS). In contrast, in pts with 
RVI but reperfusion failure, survival was strikingly lower (40% vs. 90%. p=O.O3). Conclu- 
sions: These results demonstrate that even in elderly pts with RVI. successful reperfu- 
sion by primary angioplasty is associated with excellent outcome, with survival similar to 
that achieved in IMI without RVI. In contrast, lack of successful reperfusion in the elderly 
wth RVI is associated with dismal outcome. 
1071-115 Female Gender Is the Strongest Predictor of Major 
Hemorrhage in Trials of Combination of Fibrinolytic and 
Glycoprotein IlbAlla Inhibitors 
Stephen D. Wwiott, Robert P. Giugliano, David A. Morrow, Uwe Zeymer. Matthew T. 
Roe, Robert A. Harrington, Brigham & Women’s Hospital, Boston, MA, Duke Clinical 
Research Institute. Durham, NC 
Background: Bleeding is the major adverse effect of modern pharmacologic therapy for 
myocardial infarction (Ml), and the major limitation of the use of combination fibrinolytic 
and GP Ilb/llla therapy. Identification of patients who are at Increased rusk for bleedrng is 
desirable to aid in decision-making regarding the use of these agents. We sought to 
examrne risk factors for bleeding in trials of the use of fibrinolytic +I- GP llbillla inhibitors 
for acute Ml. 
Methods: In hw AMI clinical trials (fibrinolytic +/- GP Ilb/llla Inhibitor) adludicated bleed- 
ing events using standard TIMI definitions were examined and compared to clinical char- 
acteristics. 
Results: of1573 patients (23% women), 97 patients (8.2%) had major hemorrhage (51 
women (14.2%) and 46 men (3.8%) odds ratio 4.2, Cl 2.8-6.4, PcO.OOl]. When adjusted 
for univariate predictors, female gender remained the strongest independent predictor of 
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major hemorrhage with a greater than three-fold increase in risk of major hemorrhage 
(table). 
Conclusions: Female gender is a significant risk factor for bleeding in AMI trials combin- 
rng fibrrnolytics and GP Ilb/llla inhibitors, independent of age, weight, and creatrnine 
clearance. Recognition of patients at increased risk for hemorrhage may aid in the choice 
of therapy for AMI, use of adjunctive therapies to reduce risk, and in designing future clin- 
ical trrals. 
Characteristic 
Gender (F) 
Age (10 Y) 
CrCl(l0 mkmin) 
Weight (10 kg) 
OR Cl Z P 
3.3 2.1 - 5.3 5.1 0.001 
1.5 1.2 - 1.8 2.5 0.02 
1.04 1.00-1.07 2.2 0.03 
0.89 0.76 - 1.03 -1.5 0.15 
1071-116 Do Baseline C-Reactive Protein Levels Predict 
Myocardial Salvage After Reperfusion Therapy in 
Patients With Acute Myocardial Infarction? 
Alban Dibra, Julinda Mehilli, Helmut Schuehlen, Juergen Pache, Jodi Neverve, Adnan 
Kastrati, Albert Schomig, Deutsches Herzzentrum Muenchen, Muenchen, Germany, 
Klinik fuer Nuklearmedizin rechts der Isa,, TU Muenchen, Germany 
The prognostic value of C-reactive protein (CRP) measured on admission in patients 
(pts) with acute myocardial infarction (AMI) treated with reperfusion therapies and its 
usefulness rn guiding the selection of the appropriate therapy are not known. We studied 
the relationship between baseline CRP and myocardial salvage (MS) in patients with AMI 
treated with reperfusion therapy and its therapeutical implications. The study population 
consisted in 302 pts of STOPAMI 1 and 2 randomized trials that compared stentrng (plus 
abcixmab) with thrombolysis (full-dose alone or half-dose plus abciximab) in AMI. CRP 
levels measured by a high sensitivity assay were available in 288 pts. The threshold of 
12 mgfdl (upper quartile limit) defined the group with high CRP (73 pts) and low CRP 
(215 pts). Two technetium-99m sestamibi studies were performed to calculate inrtial per- 
fusion defect, final infarct size and salvage index. Pts with high CRP had less MS (0.29 
vs. 0.47, P=O.O09) and higher l-year mortality (16.4% vs. 6.0%, P=O.O06) than pts with 
low CRP. The correlation between CRP and MS was confined to pts treated with throm- 
bolysis alone and was eliminated when stenting or thrombolysis were combined wrth 
abciximab (Figure). 
Conclusion: In pts with AMI, high CRP levels at baseline may be associated with less 
myocardial salvage achieved by reperfusion. Pts with high CRP may benefit from the 
addition of abciximab. 
POSTER SESSION 
1072 Acute Coronary Syndromes: Clinical 
Outcome 
Monday, March 31, 2003, 9:00 a.m.-l 1:OO a.m. 
McCormick Place, Hall A 
Presentation Hour: 9:00 a.m.-10:OO a.m. 
1072-100 Impact of Reocclusion on Long-Term Survival 
Following Fibrinolytic Therapy: lo-Year Follow-Up of 
the APRICOT-1 Trial 
Peter C. Kievit, Marc A. Brouwer, HendrikJan Dicker, Gerrit Veen. Freek W. A. 
Verheugt, Free University Medical Center, Amsterdam, The Netherlands, Heartcenter, 
University Medical Center, Nijmegen, The Netherlands 
Background: Reocclusion after successful fibrinolysis occurs in about 30% of patients, 
the majority in the absence of clintcal reinfarction: asymptomatic reocclusion. Whereas 
early symptomatic reocclusion has been associated with a twofold increased rusk of mor- 
tality, the prognostic impact of reocclus~on after the acute phase remains to be deter- 
mined. 
Methods: In the APRICOT-l trial 248 patients had an open infarct related artery at 
angiography < 48 hours, with follow-up angiography at 3 months. Outcome was recorded 
using medical charts and rnformation from the general physician and municipal registries. 
Results:: Reocclusion was observed in 71 patients (29%). Mean clinical follow-up was 
9.8c3.4 years, 71% having mc~re than 10 years follow-up. No difference in death from 
any cause was observed between patients wrth and without reocclusion. However, lo- 
year cardiac death was higher in those with reocclusion: 22% vs. 11% (Figure, p = 0.06). 
This difference was primarily caused in the subset of patients in whom 3.month reccclu- 
